Introduction to Talquetamab and Its Clinical Context
Multiple myeloma (MM) is a malignant plasma cell disorder characterized by clonal proliferation of abnormal plasma cells primarily in the bone marrow. Patients with true extramedullary myeloma (plasmacytomas outside the bone marrow) represent a subset with poor prognosis and a high risk of relapse or disease progression due to drug resistance and sanctuary site involvement. Treatment options historically have been limited and often ineffective in this setting.
Talquetamab is a bispecific antibody that targets G protein-coupled receptor family C group 5 member D (GPRC5D) on myeloma cells and CD3 on T cells, directing T-cell mediated killing of myeloma cells. This therapy has emerged as a promising option in heavily pretreated, relapsed or refractory multiple myeloma (RRMM) patients, including those naïve or previously exposed to T-cell redirection (TCR) therapies. Teclistamab is a bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3, which has been combined with talquetamab for dual targeting of extramedullary disease. Below is a detailed summary of two key clinical studies evaluating talquetamab, both as monotherapy and in combination with teclistamab.
Study 1: Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab (RedirecTT-1 Phase 2)
This phase 2 clinical trial specifically enrolled patients with drug-resistant, true extramedullary myeloma—a patient population with limited treatment options—who had been exposed to standard multiple myeloma therapies (triple-class exposed). The study aimed to evaluate the efficacy and safety of talquetamab plus teclistamab, utilizing dual antigen targeting to enhance anti-myeloma immune responses.
Key findings from the study included:
– Ninety patients received the combination therapy with a median follow-up of 12.6 months.
– Overall response rate (ORR) was 79%, indicating that nearly 8 in 10 patients experienced a measurable clinical benefit measured by functional imaging.
– Among responders, 64% maintained their response for at least 12 months.
– Progression-free survival (PFS) at 12 months was 61%, and overall survival (OS) was 74%, highlighting sustained disease control.
Safety profile:
– Common adverse effects included oral symptoms (such as altered taste, dry mouth, swallowing difficulties) in 87%; cytokine release syndrome (CRS) in 78%; and skin-related events without rash in 69%.
– Grade 3 or 4 adverse events were observed in 76%, predominantly hematologic toxicities, with 31% experiencing serious infections.
– Treatment discontinuation due to adverse effects occurred in 6% of patients.
– Of 10 deaths during follow-up, five were infection-related, and five were treatment-related but nonfatal.
Interpretation:
This combination therapy shows meaningful clinical activity in a difficult-to-treat population, though the incidence of high-grade adverse events warrants careful management. The dual targeting approach may offer an enhanced therapeutic benefit over single-agent treatments for extramedullary myeloma.
Study 2: Talquetamab Monotherapy in Relapsed or Refractory Multiple Myeloma (MonumenTAL-1 Phase 1-2)
MonumenTAL-1 is an extensive multicenter, open-label study investigating talquetamab monotherapy across various dosing regimens, including patients naïve or previously treated with T-cell redirection therapies.
Patient and treatment details:
– 537 treated adults with RRMM who had undergone at least three prior lines of therapy.
– Talquetamab administered subcutaneously either at 0.4 mg/kg weekly or 0.8 mg/kg every two weeks.
– Median follow-up ranged from 16.8 to 25.6 months depending on the group.
Efficacy outcomes:
– ORR was 74% for the 0.4 mg/kg weekly group, 69% for the 0.8 mg/kg biweekly group, and 67% for patients with prior TCR exposure.
– These robust response rates were maintained in patients previously treated with therapies targeting BCMA, underlining broad applicability.
Safety profile:
– Most common adverse events were cytokine release syndrome (up to 79%), taste changes (>70%), and infections (up to 76%).
– Grade 3-4 toxicities primarily included neutropenia, anemia, and lymphopenia.
– Fatal adverse events were few and not treatment-related.
Interpretation:
Talquetamab monotherapy demonstrates a strong and durable response in heavily pretreated and TCR-exposed patients, expanding treatment options for RRMM with an acceptable safety profile manageable with supportive care and monitoring.
Clinical Implications and Future Directions
Talquetamab, either as monotherapy or combined with teclistamab, represents an innovative immunotherapeutic strategy that leverages dual antigen targeting to improve outcomes in RRMM, including difficult extramedullary cases. The high response rates and durability of responses suggest a meaningful advance over existing standard therapies.
However, clinicians must remain vigilant for immune-related toxicities, including cytokine release syndrome and hematologic adverse effects, and manage them proactively to ensure patient safety.
Further research directions include:
– Optimizing dosing schedules and combinations to mitigate toxicity while maintaining efficacy.
– Investigating talquetamab in less heavily treated patient populations.
– Exploring combinations with other immunotherapies and supportive agents.
Conclusion
The studies summarized here demonstrate that talquetamab, alone or in combination with teclistamab, provides promising therapeutic options for patients with relapsed or refractory multiple myeloma, especially those with extramedullary disease. While the safety profile requires careful management, the substantial overall response rates and durability offer hope for improved disease control in this challenging patient population.
Both therapies are supported by extensive clinical evaluation and ongoing investigation, marking a significant advance in multiple myeloma immunotherapy. Clinicians should consider these novel agents in treatment planning for eligible patients with RRMM to improve outcomes and quality of life.
References:
– Kumar S, et al. Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab. N Engl J Med. 2025.
– Chari A, et al. Safety and activity of talquetamab in relapsed or refractory multiple myeloma (MonumenTAL-1). Lancet Hematol. 2025.
Funded by Johnson & Johnson and Janssen Pharmaceuticals.